All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

Takeda Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Phase 2 ELEKTRA Study of Soticlestat Meets Primary Endpoint

Lead Product(s): Soticlestat

Therapeutic Area: Neurology Product Name: TAK-935

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Ovid Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 25, 2020

Details:

Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo in the combined Dravet syndrome and Lennox-Gastaut syndrome study population.